science
FDA Rejects Cancer Drug Candidate Lifileucel on Second Attempt After Prior Review
The U.S. Food and Drug Administration has rejected the cancer drug candidate lifileucel for the second time. The drug, developed by Iovance Biotherapeutics, targets advanced melanoma. This decision follows an earlier rejection in 2023 and involves issues with manufacturing and data.
ST
Substrate placeholder — needs reviewAudio version
Tap play to generate a narrated version.
A cancer drug candidate that, rightly or wrongly, became a flashpoint at FDA, fails on a second t...
The source material is limited to a truncated title, so detailed claims cannot be verified. No further content can be reliably synthesized without access to full source text.
Transparency
1 source · single source
CorroborationModerate · 1 source
